Abstract
No public abstract is available from the verified source records.
Kyung Ah Woo, Yoonhyuk Jang, Peter J. Park
Abstract
Authors
Institutions
Provenance
crossref
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Genetically proxied GLP1R expression does not predict exenatide response in the Exenatide-PD3 trial
2026
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
10.1016/s0140-6736(24)02808-3 · 2025
GLP1R expression and Parkinson’s disease and related disorders in GLP-1 receptor agonist-treated type 2 diabetes
2026
Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy
10.1038/s41392-024-01931-z · 2024
Parkinson disease and the immune system—Associations, mechanisms and therapeutics
10.1038/s41582-020-0344-4 · 2020
Glucagon-like peptide-1 receptor agonists and risk of Parkinson's disease in patients with type 2 diabetes: A population-based cohort study
10.1002/mds.29992 · 2024
Neuroprotective trials in REM sleep behavior disorder: The way forward becomes clearer
10.1212/wnl.0000000000200235 · 2022
Peripheral blood inflammatory cytokines in idiopathic REM sleep behavior disorder
10.1002/mds.27841 · 2019
A new metabolic network correlated with olfactory and executive dysfunctions in idiopathic rapid eye movement sleep behavior disorder
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.3988/jcn.2019.15.2.175 · 2019
Genetic predictors of GLP1 receptor agonist weight loss and side effects
10.1038/s41586-026-10330-z · 2026
No additional external references are available.